The Sicca Syndrome (Sjogren) drugs in development market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sicca Syndrome (Sjogren). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued products.
GlobalData tracks 67 drugs in development for Sicca Syndrome (Sjogren) by 59 companies/universities/institutes. The top development phase for Sicca Syndrome (Sjogren) is phase ii with 23 drugs in that stage. The Sicca Syndrome (Sjogren) pipeline has 62 drugs in development by companies and five by universities/ institutes. Some of the companies in the Sicca Syndrome (Sjogren) pipeline products market are: Bristol-Myers Squibb, Amgen and Johnson & Johnson.
The key targets in the Sicca Syndrome (Sjogren) pipeline products market include B Lymphocyte Antigen CD19, CD40 Ligand, and B Cell Receptor CD22.
The key mechanisms of action in the Sicca Syndrome (Sjogren) pipeline product include CD40 Ligand Inhibitor with four drugs in Phase III. The Sicca Syndrome (Sjogren) pipeline products include 14 routes of administration with the top ROA being Intravenous and ten key molecule types in the Sicca Syndrome (Sjogren) pipeline products market including Monoclonal Antibody, and Small Molecule.
Sicca Syndrome (Sjogren) overview
Sjogren’s syndrome is an autoimmune disease. It involves the inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease.
For a complete picture of Sicca Syndrome (Sjogren)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
